Navigation Links
Cytopia Appoints Study Chairman for JAK2 Clinical Trial
Date:7/29/2008

MELBOURNE, Australia, July 29 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) has appointed Dr. Ayalew Tefferi, Professor of Medicine and Hematology at the Mayo Clinic College of Medicine, as Clinical Study Chair for the company's Phase I/II study in patients with myelofibrosis.

Dr. Tefferi is a world-renowned expert in the treatment of myeloproliferative disorders (MPDs) and has authored over 500 research publications and given many hundreds of invited lectures in haematology. He also serves on the editorial boards of a number of leading haematology journals.

Myelofibrosis patients suffer a bone marrow disorder in which the marrow is replaced by fibrous scar tissue. Patients will be treated in this study with Cytopia's novel orally available compound CYT387. This drug inhibits the mutant JAK2 enzyme to specifically treat haematological malignancies, including myelofibrosis.

Many of these particular diseases can lead to life threatening conditions such as leukemia. There are currently no effective long term treatments for these conditions.

"Cytopia is delighted that a clinician of Dr. Tefferi's standing has agreed to chair our Phase I/II program," said Mr. Andrew Macdonald, CEO. "Dr. Tefferi and our other clinical investigators will study and document the clinical benefits of using this highly promising JAK2 inhibitor to treat these blood disorders."

Following the completion of very encouraging in-vivo studies at Oregon Health and Science University early in the year, CYT387 has been undergoing rigorous IND-enabling toxicology studies in recent months. It is anticipated that an Investigational New Drug application will be lodged with the US Food and Drug Administration by the end of the year to support studies in Australia and the United States.

About JAK2

The discovery of a specific single activating mutation in the JAK2 enzyme in MPDs in 2005 has focused attention on developing a therapy for these diseases through selective inhibition of JAK2. To successfully address these chronic diseases with a JAK2 inhibitor, the specificity and resultant tolerability profile is a key element of the product profile required for a "best in class" inhibitor.

Cytopia is a world leader in JAK2 kinase chemistry and holds a broad range of JAK2 related patents. The main area of focus for the JAK2 program has been the development of orally available JAK2 inhibitors to treat myeloproliferative disorders, which include myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) CYT387 is a specific JAK2 inhibitor with excellent potential for safe and efficacious chronic human dosing. It has been derived from Cytopia's knowledge of basic biology of JAK kinases, a strong structural biology program that has delivered multiple co-crystal structures of JAK2 complexed with inhibitors, and the subsequent development of an extensive chemical library of JAK2 inhibitors through an integrated computational and medicinal chemistry platform.

Cytopia is developing a suite of JAK2 inhibitors for multiple indications including the treatment of certain cancers, particularly lymphomas and solid tumours where JAK2 has been shown to be upregulated, and for cardiovascular diseases such as pulmonary hypertension.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, and currently being trialed in Phase 1 and Phase 2 clinical studies. Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase 1 clinical studies in early 2009.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
3. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. West Pharmaceutical Services, Inc. Appoints New Director
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Curemark Appoints Preeminent Pediatrics Gastroenterologist
8. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Calif. , Feb. 5, 2016  Syneron ... global aesthetic device company, announced today that ... Candela North America, is scheduled to participate in ... Healthcare Conference on February 11, 2016 in ... will allow institutional investors to meet with the ...
(Date:2/5/2016)... Feb. 5, 2016  Patients in Alabama ... ultrasound (HIFU) therapy no longer have to travel out of ... partnership with Urology Centers of Alabama to provide ... procedure for qualifying patients. Alabama ... the treatment of prostate cancer using many different modalities. They ...
(Date:2/5/2016)... 5, 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ... CEO, will be presenting at Source Capital Group,s 2016 Disruptive ... at 2:15 p.m. ET on Wednesday, February 10, ... discussion taking place at 3:15 p.m. ET. http://www.aethlonmedical.com ... hour after the conclusion of the live event. The panel ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the ... to wait longer to access the treadmills. It’s a predictable trend. After the excesses ... weight and get in shape by joining gyms, starting new walking or running routines, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. Lydia ... No Cost Dental Day to individuals in need. The event is scheduled to take ... Cost Dental Day is to provide dental care to community members in need. Each ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... –This week, ... the benefits of having a tankless water heater. To view the report, click ... heaters: tank and tankless. While each has their pros and cons, the type chosen ...
(Date:2/4/2016)... ... 04, 2016 , ... American Addiction Centers (AAC) and Holdspace ... Project HoldSpace. Through the partnership, the two organizations seek to tackle the widespread ... ages of 13 and 18. Currently focused on Ohio schools, the first leg ...
Breaking Medicine News(10 mins):